



MARKET RELEASE

26 July 2017

Cogstate Ltd

TRADING HALT

The securities of Cogstate Ltd (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Friday, 28 July 2017 or when the announcement is released to the market.

Security Code: CGS

James Gerraty
MANAGER, LISTINGS COMPLIANCE (MELBOURNE)



26 July 2017

James Gerraty
Advisor, Listings Compliance
ASX Limited
Level 4
North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

Dear James

Cogstate Ltd (**Company**) requests an immediate trading halt be granted by ASX with respect to its securities (ASX code: CGS).

The trading halt is requested by Cogstate pending an announcement to the market in connection with its 510(k) submission to the U.S. Food and Drug Administration (FDA) for the Cogstate COGNIGRAMTM System.

In accordance with ASX Listing Rule 17.1, the Company provides the following information:

- (a) The trading halt is necessary as otherwise trading in the Company's securities might occur while the market as a whole is not reasonably informed.
- (b) The Company requires the trading halt from 26 July 2017 and continuing until the earlier of the Company making an announcement to ASX concerning the potential placement and the commencement of trading on Friday, 28 July 2017.
- (c) The Company expects an announcement concerning the 510(k) submission will be made prior to the commencement of trading on Thursday, 27 July 2017.
- (d) The Company is not aware of any reason why the trading halt should not be granted.
- (e) The Company is not aware of any other information necessary to inform the market about the trading halt.

Yours faithfully

Brad O'Connor
Managing Director